Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Findings from Erasmus University provide new insights into cancer vaccines
March 11th, 2009
"A panel of cytokine-secreting RM-9 prostate cancer cells were tested as whole cell vaccines to determine their capacity to evoke an anti-prostate cancer immune response," investigators in Netherlands report. "In our model, vaccines secreting mGM-CSF or mIL-7 resulted in the highest increase in circulating T lymphocytes after vaccination, prolonged survival and, in a proportion of animals, tumor-free survival. Anti-tumor effects were more evident after a subcutaneous RM-9 challenge than after an intraprostatic challenge," wrote C. Schrotenloef and colleagues, Erasmus University. The researchers concluded: "However, when the RM-9/mGM-CSF cell line was...
Source: Vaccine Weekly (2009-03-11)
|
